An interventional study of Reia System and Standard of Care Pessary in Pelvic Organ Prolapse and Prolapse, sponsored by Medstar Health Research Institute. Active, not recruiting at 9 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Medstar Health Research Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 195 studies in Pelvic Organ Prolapse with a site in United States — 12 open to participants now, 23 under way, none of them phase 3. Pelvic Organ Prolapse · United States.
Among the 195 studies in Pelvic Organ Prolapse with a site in United States, this one is the 13th largest by planned enrollment of the 133 interventional ones that give a count, is one of 5 that started in 2024, is one of 90 with no phase, reaches primary completion later than 12 of the 22 other live ones, and was the 184th registered.
522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.
Browse Pelvic Organ Prolapse studies →12 of the 195 studies in Pelvic Organ Prolapse with a site in United States are open now. Recruiting first, the newest first:
Ohio State University · Sites in United States
Ages 18+ · Women only
Cassandra Kisby · Sites in United States
Ages 21+ · Women only
The Cleveland Clinic · Sites in United States
Ages 18+
NICHD Pelvic Floor Disorders Network · Sites in United States
Ages 18–99 · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
195 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 9 · Phase 4 25
First in 1996; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 218 is above the median of 80 across 337 interventional studies indexed under Pelvic Organ Prolapse.
Median enrollment 78 across the 133 interventional studies, 103 across the 61 observational. Of the 154 that completed or were terminated, 51 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 195 have an industry lead sponsor. The 10 most frequent:
Medstar Health Research Institute is the lead sponsor of 162 studies on the registry; 32 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
Medstar Health Research Institute has 5 studies filed under Pelvic Organ Prolapse — fewer than ten, so there is no comparison to draw.
8 of the studies in Pelvic Organ Prolapse with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04179955Mayo ClinicIntraoperative Costs and Patient Perceptions in Sacrocolpopexy for Prolapse | 2026-12 |
| NCT06634459Medstar Health Research InstitutePOMEGRANATE Trial: Comparing Reia Pessary Versus Standard of Care Pessary for Pelvic Organ Prolapse Treatment | 2027-01 |
| NCT07008898University of Alabama at BirminghamSequence of Midurethral Sling Placement During Robotic Sacrocolpopexy | 2027-05 |
| NCT07692789Ohio State UniversityImproving Uroflowmetry Interpretability: Evaluating the Impact of Patient Reminder Systems | 2027-06 |
| NCT07218016NICHD Pelvic Floor Disorders NetworkAccelerometer Measured Early Recovery After Prolapse Surgery | 2027-06-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 195 studies in Pelvic Organ Prolapse with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multi-centered, randomized controlled trial will evaluate the safety and efficacy of home use of the novel Reia System (RS), which includes the Reia pessary and applicator, compared to standard pessary care (Gellhorn or ring with/without support without knob) among women with stage II-IV pelvic organ prolapse (POP). A total of 200 participants will be recruited among pessary naïve patients who are symptomatic and choose a vaginal pessary for management of their POP from study sites specializing in Urogynecology and Reconstructive Pelvic Surgery (URPS). Participants will be assigned via 1:1 randomization using computer generated numbers in permutated groups of variable block sizes to either the intervention (the Reia System, RS) or standard pessary care (SPC) stratified by site. Participation in this trial will involve a total of four visits over six months. The primary outcome measure will be satisfaction measured at the six-month time point. Secondary outcomes will include validated surveys to assess quality of life, number of self-management events, ease/difficulty of pessary insertion/removal, importance of ability to self-manage pessary, and adverse events.
Specific Aims
Aim 1: To compare satisfaction with pessary use and management between subjects randomized to the Reia System and those randomized to standard of care pessary.
Aim 2: To assess successful fitting, number of refitting visits, number of self-management events and continued pessary use over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary.
Aim 3: To compare ease/difficulty of pessary use and importance of ability to self-manage, as well as quality of life over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary.
Aim 4: To measure rates of adverse events and risk factors for adverse events over a 6-month period between subjects randomized to the Reia System and those randomized to standard of care pessary.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of hydroureter, hydronephrosis, or impaired renal function secondary to prolapse
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receiving the commercially available RS will be fit with one of three available pessary sizes and will receive an applicator corresponding to their pessary size.
Device: Reia System
Participants receiving SPC will be fit with a Gellhorn pessary or ring with/without support without knob pessary per standard clinical protocol.
Device: Standard of Care Pessary
Reia pessary
Gellhorn pessary or ring with/without support without knob pessary
Satisfaction with treatment
The primary outcome will be measured by participant response to the question "How satisfied or unsatisfied are you with your ability to use and manage the pessary provided to you?" with response collected via VAS ranging from "0mm = very unsatisfied" to "100mm = very satisfied" with 50mm = neutral (neither satisfied nor unsatisfied).
Time frame: 6 months
Total self-management events
Defined as removing the pessary ≥ one time per 24-hour period over the six-month follow-up period, this outcome will be summed and divided by actual days of follow-up to accommodate minor variation across participants in the exact length of follow-up.
Time frame: 6 months
Patient Global Impression of Severity (PGI-S)
A single item questionnaire to assess the patient's impression of disease severity. For purposes of this trial, the investigators have adapted the PGI-I to specifically ask about "prolapse" severity. It will ask participants to "Check the one number that best describes how the participant's prolapse condition is now" on a 4-point Likert scale ranging from (1) normal to (4) severe
Time frame: 6 months
Patient Global Impression of Improvement (PGI-I)
A single item questionnaire to assess a patient's impression of change. For purposes of this trial, the investigators have adapted the PGI-I to specifically ask about "prolapse symptoms." It will ask participants to "Check the one number that best describes how the participant's prolapse condition is now, compared with how it was before the participant began this study" on a 7-point Likert scale ranging from (1) very much better to (7) very much worse
Time frame: 6 months
Pelvic Floor Distress Inventory-20 (PFDI-20)
A 20-item condition-specific quality-of-life instrument with three scales (6-item Urinary Distress Inventory, 6-item Pelvic Organ Prolapse Distress Inventory, and 8-item Colorectal-Anal Distress Inventory) used to evaluate the impact of pelvic floor disorders on quality of life with a response scale from 0 (not present) to 4 (quite a bit bothersome).
Time frame: 6 months
Pelvic Floor Impact Questionnaire-7 (PFIQ-7)
A 7-item condition-specific quality-of-life instrument with three scales (Urinary, Pelvic Organ Prolapse, and Colorectal-Anal). The PFIQ-7 is a validated instrument that is widely utilized in research in conjunction with the PFDI-20 to provide a comprehensive evaluation of the impact of pelvic floor disorders on quality of life, specifically how they affect activities, relationships, and feelings on a scale from not at all to quite a bit.
Time frame: 6 months
Patient Global Symptoms Control Rating Scale (PGSC)
A a single item adapted for purposes of this trial. It will state "My current treatment is giving me adequate control of my prolapse" and participants will be asked to select a response on a 5-point Likert scale ranging from (1) disagree strongly to (5) agree strongly
Time frame: 6 months
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR)
A validated instrument to evaluate sexual function in women with pelvic organ prolapse and/or urinary incontinence with 21 questions for sexually active women and 12 questions for non-sexually active women
Time frame: 6 months
Pessary outcomes
Will include continued use of pessary and number of unintentional pessary expulsions
Time frame: 6 months
Behavioral Outcomes
Will include a 5-point Likert scale ranging from (1) disagree strongly to (5) agree strongly about participants' ease of self-administered pessary insertion, ease of self-administered pessary removal, discomfort with self-administration of pessary insertion, and discomfort with self-administration of pessary removal
Time frame: 6 months
Participant view of importance of ability to self-maintain pessary
This outcome will be measured by the question "How important is it to you to be able to self-manage your pessary?" with response options on a 5-point Likert scale of 1-not at all important, 2-slightly important, 3-neutral, 4-moderately important, 5-very important.
Time frame: 6 months
Plan to share: No
Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.
Of 162 non-industry interventional studies with no phase under Pelvic Organ Prolapse, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 26 months is above that.
Counting every sponsor, half of 179 studies reached it within 23 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medstar Health Research Institute →